Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Could Moderna Beat Novavax to Market With a COVID-Flu Vaccine?
Could Moderna Beat Novavax to Market With a COVID-Flu Vaccine?
Could Moderna Beat Novavax to Market With a COVID-Flu Vaccine?
Submitted by
admin
on January 30, 2022 - 11:55am
Source:
Motley Fool
News Tags:
Moderna Therapeutics
Novavax
COVID-flu-RSV vaccine
NanoFlu
vaccines
Headline:
Could Moderna Beat Novavax to Market With a COVID-Flu Vaccine?
snippet:
Moderna's CEO recently said that his company could have a COVID-flu-RSV vaccine ready before the winter of 2023.
Novavax has a flu vaccine candidate, NanoFlu, that performed well in phase 3 testing.
Novavax is testing a combo of its COVID-19 vaccine with NanoFlu.
Do Not Allow Advertisers to Use My Personal information
